J&J-Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors

Stock Performance - Johnson & Johnson (JNJ) closed at $146 18, marking a +1 75% increase from the previous day, outperforming the S&P 500's daily loss of 1 11% [1] - Over the past month, JNJ shares lost 3 97%, outperforming the Medical sector's loss of 6 22% but lagging behind the S&P 500's loss of 1 7% [1] Earnings and Revenue Forecast - JNJ's upcoming earnings report is set for January 22, 2025, with an expected EPS of$ 2, indicating a 12 66% decline compared to the same quarter last year [2] - Revenue is anticipated to be $22 54 billion, reflecting a 5 37% increase from the same quarter last year [2] Analyst Revisions and Zacks Rank - Recent revisions to analyst forecasts for JNJ reflect changing near-term business trends, with positive revisions indicating optimism about the company's profitability [3] - The Zacks Consensus EPS estimate has increased by 0 03% over the last 30 days, and JNJ currently holds a Zacks Rank of 2 (Buy) [5] - The Zacks Rank system has a strong track record, with 1 stocks generating an average annual return of +25% since 1988 [5] Valuation Metrics - JNJ's Forward P/E ratio is 13 62, representing a premium compared to the industry average of 12 34 [6] - The company's PEG ratio is 2 33, higher than the Large Cap Pharmaceuticals industry average of 1 26, indicating a higher valuation relative to expected earnings growth [7] Industry Overview - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 191, placing it in the bottom 24% of all industries [8] - Industries in the top 50% of the Zacks Industry Rank outperform the bottom half by a factor of 2 to 1 [8]